Eligibility typically requires a BMI of 30 or higher, or 27+ with weight-related health conditions
Oral formulations may expand access to treatment, particularly for those reluctant to use injectable medications
The cheapest sustainable path is a U.S.-licensed 503A pharmacy with a real prescription, not a grey-market workaround
Factors such as current weight, age, health status, activity level, and consistency with treatment and follow-up can all influence your individual weight loss experience
Wegovy works by mimicking a natural hormone that helps regulate appetite and digestion
In a phase 2 clinical trial for obesity, 26 weeks of efinopegdutide (doses 5 to 10mg) resulted in up to 11.8% WL in people with obesity (without diabetes) compared to 7.5% WL with liraglutide 3 mg and 1.8% WL with placebo [77, 78]